It’s been a humbling first half of the year for health tech companies.
Previously abundant venture funding for health companies continues to shrink, and a growing number face unprecedented legal and regulatory challenges. Virtual care pioneer Teladoc, hobbled by the unprofitable acquisition of Livongo, is being sued for misleading investors. Cerebral, an online company that virtually prescribed controlled substances including Adderall, is under dual investigations by the Federal Trade Commission and the Drug Enforcement Agency for its marketing and prescribing practices.
But the sector seems determined to push through as companies and regulators resume in-person industry gatherings and virtual summits aimed at navigating increasingly complex questions about funding, regulation, and the fair and equitable deployment of health technology.
Create a display name to comment
This name will appear with your comment
